JP5816100B2 - 多能性細胞の分化 - Google Patents

多能性細胞の分化 Download PDF

Info

Publication number
JP5816100B2
JP5816100B2 JP2011552223A JP2011552223A JP5816100B2 JP 5816100 B2 JP5816100 B2 JP 5816100B2 JP 2011552223 A JP2011552223 A JP 2011552223A JP 2011552223 A JP2011552223 A JP 2011552223A JP 5816100 B2 JP5816100 B2 JP 5816100B2
Authority
JP
Japan
Prior art keywords
cells
differentiation
medium
cell
pluripotent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011552223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012519005A5 (enExample
JP2012519005A (ja
Inventor
ディーピカ ラジェシュ，
ディーピカ ラジェシュ，
レイチェル ルイス，
レイチェル ルイス，
Original Assignee
セルラー ダイナミクス インターナショナル， インコーポレイテッド
セルラー ダイナミクス インターナショナル， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルラー ダイナミクス インターナショナル， インコーポレイテッド, セルラー ダイナミクス インターナショナル， インコーポレイテッド filed Critical セルラー ダイナミクス インターナショナル， インコーポレイテッド
Publication of JP2012519005A publication Critical patent/JP2012519005A/ja
Publication of JP2012519005A5 publication Critical patent/JP2012519005A5/ja
Application granted granted Critical
Publication of JP5816100B2 publication Critical patent/JP5816100B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2011552223A 2009-02-27 2010-03-01 多能性細胞の分化 Active JP5816100B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15630409P 2009-02-27 2009-02-27
US61/156,304 2009-02-27
PCT/US2010/025776 WO2010099539A1 (en) 2009-02-27 2010-03-01 Differentiation of pluripotent cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015158092A Division JP2015192681A (ja) 2009-02-27 2015-08-10 多能性細胞の分化

Publications (3)

Publication Number Publication Date
JP2012519005A JP2012519005A (ja) 2012-08-23
JP2012519005A5 JP2012519005A5 (enExample) 2013-04-18
JP5816100B2 true JP5816100B2 (ja) 2015-11-18

Family

ID=42097524

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011552223A Active JP5816100B2 (ja) 2009-02-27 2010-03-01 多能性細胞の分化
JP2015158092A Pending JP2015192681A (ja) 2009-02-27 2015-08-10 多能性細胞の分化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015158092A Pending JP2015192681A (ja) 2009-02-27 2015-08-10 多能性細胞の分化

Country Status (9)

Country Link
US (2) US8372642B2 (enExample)
EP (1) EP2401364B1 (enExample)
JP (2) JP5816100B2 (enExample)
KR (1) KR101720961B1 (enExample)
CN (1) CN102388130B (enExample)
AU (1) AU2010217739B2 (enExample)
CA (1) CA2753679C (enExample)
IL (1) IL214818A (enExample)
WO (1) WO2010099539A1 (enExample)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3712258B1 (en) 2006-04-14 2025-01-01 Astellas Institute for Regenerative Medicine Hemangio-colony forming cells
US8741644B2 (en) 2009-09-08 2014-06-03 Kyoto University Method for producing mast cells from pluripotent stem cells
EP2499236B1 (en) 2009-11-12 2020-01-01 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
WO2011068792A2 (en) * 2009-12-01 2011-06-09 The Regents Of The University Of California Compositions and methods for making and using bone marrow mesenchymal stem cells and erythroid progenitor cells
RU2012127811A (ru) * 2009-12-04 2014-01-10 Стем Селл Энд Ридженерэйтив Медсин Интернэшнл, Инк. Способ получения клеток-натуральных киллеров и дендритных клеток из человеческих эмбриональных гемангиобластов, полученных из стволовых клеток
WO2011106681A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University SMOOTH MUSCLE-LIKE CELLS (SMLCs) DERIVED FROM HUMAN PLURIPOTENT STEM CELLS
US8691574B2 (en) 2010-06-15 2014-04-08 Cellular Dynamics International, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
US8765470B2 (en) 2010-08-04 2014-07-01 Cellular Dynamics International, Inc. Reprogramming immortalized B-cells to induced pluripotent stem cells
JP5597904B2 (ja) 2010-09-10 2014-10-01 国立大学法人 東京大学 多能性幹細胞からの血液細胞分化に関する培養方法
WO2012103098A2 (en) * 2011-01-24 2012-08-02 Immunepath, Inc. Compositions and methods for treating hematological cytopenias
JP6148429B2 (ja) * 2011-01-31 2017-06-14 協和発酵バイオ株式会社 ヒト多能性幹細胞の培養方法
EP2673358B1 (en) * 2011-02-08 2019-01-09 FUJIFILM Cellular Dynamics, Inc. Hematopoietic precursor cell production by programming
CN102161980B (zh) * 2011-02-12 2013-07-31 浙江大学 用人间充质干细胞为滋养层培养诱导多能干细胞的方法
WO2012115276A1 (en) 2011-02-23 2012-08-30 Kyoto University Method for producing dendritic cells from pluripotent stem cells
US9169309B2 (en) * 2011-03-01 2015-10-27 Humanzyme Inc. Thermostable variants of fibroblast growth factors
GB201103600D0 (en) * 2011-03-01 2011-04-13 Isis Innovation Dendritic cells
US9487752B2 (en) 2011-03-30 2016-11-08 Cellular Dynamics International, Inc. Priming of pluripotent stem cells for neural differentiation
CN103620024B (zh) * 2011-06-09 2016-06-22 弗·哈夫曼-拉罗切有限公司 用于使多能干细胞分化为血管床细胞的方法
LT2761065T (lt) * 2011-09-29 2018-01-10 Cellsnap, Llc Kompozicijos ir būdai toksigeniškumo testavimui
US20140227780A1 (en) * 2011-10-03 2014-08-14 Nissan Chemical Industries, Ltd. Method for producing megakaryocytes and/or platelets from pluripotent stem cells
CA2856322C (en) * 2011-11-21 2021-10-12 University Health Network Populations of hematopoietic progenitors and methods of enriching stem cells therefor
KR102108245B1 (ko) 2011-11-30 2020-05-08 아스텔라스 인스티튜트 포 리제너러티브 메디슨 중간엽 간질 세포 및 이에 관련된 용도
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
EP3653698B1 (en) 2011-12-01 2025-04-02 New York Stem Cell Foundation, Inc. Automated system for producing induced pluripotent stem cells or differentiated cells
US10428309B2 (en) 2011-12-01 2019-10-01 New York Stem Cell Foundation, Inc. Systems and methods for producing stem cells and differentiated cells
AU2013225946B2 (en) * 2012-02-29 2018-07-12 The Johns Hopkins University Method for guiding the derivation of endothelial cells from human pluripotent stem cells employing two-dimensional, feeder-free differentiation
WO2013163171A1 (en) 2012-04-24 2013-10-31 Kaufman Dan S Method for developing natural killer cells from stem cells
GB201210857D0 (en) 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
CN114164174A (zh) * 2012-09-28 2022-03-11 公益财团法人神户医疗产业都市推进机构 含有适合用于缺血性疾病治疗的细胞的细胞群体的体外增殖方法
MX2015006301A (es) 2012-11-21 2015-09-07 Merz Pharma Gmbh & Co Kgaa Medios y metodos para la determinacion de la actividad biologica de la neurotoxina botulinica.
EP3973967A1 (en) * 2012-12-21 2022-03-30 Astellas Institute for Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
CA3141731A1 (en) 2013-03-13 2014-10-09 Wisconsin Alumni Research Foundation Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions
US9994825B2 (en) 2013-03-15 2018-06-12 The Johns Hopkins University Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix
CA2906188A1 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix
US9506037B2 (en) 2013-03-15 2016-11-29 The Johns Hopkins University Self-organized vascular networks from human pluripotent stem cells in a synthetic matrix
CN105408472A (zh) * 2013-03-15 2016-03-16 马卡斯凯尔·托莱夫·拉尔森 用于脐带血收集及细胞分离的细胞、方法和装置
JP6429280B2 (ja) * 2013-05-14 2018-11-28 国立大学法人京都大学 効率的な心筋細胞の誘導方法
JP5511039B1 (ja) * 2013-05-22 2014-06-04 国立大学法人九州大学 Ｎｋ細胞の調製方法
WO2014189144A1 (ja) * 2013-05-23 2014-11-27 国立大学法人京都大学 骨髄異形成症候群等の治療／予防薬のスクリーニング方法
WO2014200340A1 (en) * 2013-06-10 2014-12-18 Academisch Ziekenhuis Leiden Differentiation and expansion of endothelial cells from pluripotent stem cells and the in vitro formation of vasculature like structures
PL3014267T3 (pl) 2013-06-28 2019-05-31 Merz Pharma Gmbh & Co Kgaa Środki i sposoby określania aktywności biologicznej polipeptydów neurotoksyny w komórkach
WO2015050963A1 (en) * 2013-10-01 2015-04-09 Manfred Boehm Human ipsc-derived vascular-related and hematopoetic cells for therapies and toxicology/drug screenings
US11352606B2 (en) * 2014-02-10 2022-06-07 The Johns Hopkins University Low oxygen tension enhances endothelial fate of human pluripotent stem cells
BR112016019104A2 (pt) 2014-02-19 2017-10-10 Merz Pharma Gmbh &Co Kgaa método para padronizar a sensibilidade de neurônios, método para a geração de neurônios, método para determinar a atividade biológica, uso de gt1b
CA2945393C (en) 2014-04-24 2021-03-23 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
CN103937743B (zh) * 2014-04-27 2017-12-01 浙江大学 一种利用三维诱导系统获得造血干细胞的方法
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
CN107207586B (zh) 2014-12-19 2021-07-13 莫茨药物股份两合公司 用于测定BoNT/E在细胞中的生物活性的装置和方法
US10724003B2 (en) 2015-01-16 2020-07-28 Agency For Science, Technology And Research Method of differentiating human pluripotent stem cells into primitive macrophages
US9828634B2 (en) 2015-01-22 2017-11-28 Regenerative Medical Solutions, Inc. Markers for differentiation of stem cells into differentiated cell populations
US10626372B1 (en) * 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
TWI704156B (zh) 2015-03-04 2020-09-11 德商曼茲法瑪股份有限公司 用於增進肉毒桿菌神經毒素進入細胞之特定攝取的方法
WO2016187459A1 (en) * 2015-05-20 2016-11-24 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
WO2016203477A1 (en) * 2015-06-18 2016-12-22 Yeda Research And Development Co. Ltd. Conditioning protocols and use of same for tissue regeneration
ES2971677T3 (es) 2015-09-08 2024-06-06 Sumitomo Pharma Co Ltd Método para la producción de tejido retiniano
US10865381B2 (en) * 2015-10-20 2020-12-15 FUJIFILM Cellular Dynamics, Inc. Multi-lineage hematopoietic precursor cell production by genetic programming
TWI812584B (zh) 2015-10-30 2023-08-21 美國加利福尼亞大學董事會 從幹細胞產生t細胞之方法及使用該t細胞之免疫療法
CN108473961B (zh) 2015-11-04 2022-11-29 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
KR20250141836A (ko) 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
CN105296428A (zh) * 2015-12-03 2016-02-03 广州医科大学附属第三医院 一种提高诱导多能干细胞的体外分化造血效率的方法
JP6979687B2 (ja) * 2015-12-29 2021-12-15 アイ ピース インク 幹細胞の凝集塊の集団の調製方法
GB201601503D0 (en) 2016-01-27 2016-03-09 Isis Innovation Dendritic cells
EP3690022A1 (en) 2016-05-18 2020-08-05 Keio University Cell culture medium for culturing organoid, culture method, and organoid
US20190161726A1 (en) * 2016-07-29 2019-05-30 Daikin Industries, Ltd. Differentiated cell production method and culture bag used therefor
CN109963940A (zh) * 2016-09-02 2019-07-02 宝生物工程株式会社 从多能干细胞获得小胶质细胞的方法
CA3035660A1 (en) 2016-09-06 2018-03-15 The Children's Medical Center Corporation Immune cells derived from induced pluripotent stem cell
BR112019006910A2 (pt) * 2016-10-05 2019-07-02 Fujifilm Cellular Dynamics Inc métodos para diferenciação dirigida de células-tronco pluripotentes para células imunes homozigóticas de hla
ES3009605T3 (en) 2016-10-05 2025-03-27 Fujifilm Cellular Dynamics Inc Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
CN106479968A (zh) * 2016-10-11 2017-03-08 海南博鳌龄迈迪精准医学研究院有限公司 脐带间充质干细胞的培养方法
US11542473B2 (en) 2016-10-21 2023-01-03 Amniotics Ab Methods and compositions for generating hematopoietic cells
CN106754684A (zh) * 2017-01-05 2017-05-31 厚朴生物科技（苏州）有限公司 一种睾丸间质干细胞分离培养分化方法
EP3587560A4 (en) 2017-01-27 2020-12-16 Kaneka Corporation Endodermal cell mass, and method for producing any one of three primary germ layer cell mass from pluripotent cells
CN110520167B (zh) * 2017-02-03 2023-03-24 康奈尔大学 稳定的三维血管和形成其的方法
CN119955724A (zh) * 2017-03-21 2025-05-09 法国血液机构 改进造血移植物的方法
MX2019011897A (es) 2017-04-18 2019-11-28 Fujifilm Cellular Dynamics Inc Celulas efectoras inmunitarias especificas de antigenos.
EP3399027A1 (en) 2017-05-04 2018-11-07 Medizinische Hochschule Hannover Stem-cell derived myeloid cells, generation and use thereof
CN107083367B (zh) * 2017-07-03 2020-07-14 广州润虹医药科技股份有限公司 培养基及其用途与由尿液细胞制备间充质干细胞的方法
US20200131476A1 (en) * 2017-12-11 2020-04-30 Korea Center For Disease Control And Prevention Differentiation Of Immunocytes Using Pluripotent Stem Cells
WO2019126146A1 (en) 2017-12-19 2019-06-27 Xcell Biosciences, Inc. Methods of modulating cell phenotype by way of regulating the gaseous environment
CN108048390B (zh) * 2017-12-21 2021-04-27 清华大学 一种制备血管内皮细胞的方法及其专用试剂盒
CN108588024B (zh) * 2017-12-29 2020-04-21 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） 诱导多能干细胞分化成造血干细胞的培养基及方法
MX2020007071A (es) * 2018-01-05 2020-11-11 Platelet Biogenesis Inc Composiciones y metodos para producir megacariocitos.
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
FR3079239A1 (fr) * 2018-03-23 2019-09-27 Centre National De La Recherche Scientifique Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations
WO2020006539A1 (en) 2018-06-29 2020-01-02 Platelet Biogenesis, Inc. Compositions for drug delivery and methods of use thereof
EP3853351A1 (en) 2018-09-19 2021-07-28 FUJIFILM Cellular Dynamics, Inc. Protein l for activation and expansion of chimeric antigen receptor-modified immune cells
CN109266618B (zh) * 2018-10-18 2021-04-23 赛元生物科技(杭州)有限公司 能够靶向肿瘤细胞的巨噬细胞及其制备方法
AU2019368313A1 (en) * 2018-10-24 2021-05-20 Hebecell Corporation Methods and systems for manufacturing hematopoietic lineage cells
KR102111441B1 (ko) * 2018-11-12 2020-05-15 대한민국 전분화능 줄기세포 유래 대식세포를 기반으로 하는 감염질환 치료용 약물 스크리닝 방법
US12258583B2 (en) 2018-12-20 2025-03-25 Sumitomo Chemical Company, Limited Embryonic erythroblast-containing cell population and method for producing same, cell culture composition, and compound test method
JP7634938B2 (ja) * 2019-02-21 2025-02-25 ピービーエス バイオテック インコーポレイテッド バイオリアクターにおける治療細胞の膨張および分化のためのシステムおよび方法
CN111206017B (zh) * 2019-04-30 2022-02-18 浙江大学 一种干细胞无血清培养基及其应用
CA3143332A1 (en) * 2019-06-14 2020-12-17 FUJIFILM Cellular Dynamics, Inc. Methods for the production of multiple lineages from induced pluripotent stem cells using charged surfaces
EP3986358A4 (en) 2019-06-20 2023-06-21 Amniotics AB DEVICE FOR FILTERING FRUIT WATER
US20220372444A1 (en) 2019-10-18 2022-11-24 Amniotics Ab Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof
JP7479466B2 (ja) * 2019-11-13 2024-05-08 カリス バイオ インコーポレイテッド 血管内皮細胞純粋分離方法、血管内皮細胞特性維持培地及びそれを含む培養方法
CN110938584B (zh) * 2019-11-25 2021-12-03 广州赛莱拉干细胞科技股份有限公司 一种人胚胎干细胞向内皮细胞诱导分化的方法
EP4076657A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
EP4076661A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
US20230097226A1 (en) * 2020-02-28 2023-03-30 Purdue Research Foundation Generating aorta-gonad-mesonephros-like hematopoietic cells from human pluripotent stem cells under a defined condition
CN111440760B (zh) * 2020-03-09 2022-09-23 浙江大学 一种人多能干细胞高效分化得到内皮祖细胞的方法
US12220445B2 (en) 2020-03-09 2025-02-11 Amprion, Inc. Inert matrices for qualitative and semi-quantitative seed amplification assays
US11547726B2 (en) * 2020-03-26 2023-01-10 Honed Life Sciences, Llc Enhancement of production of NK cells from stem cells
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
JPWO2021256522A1 (enExample) 2020-06-17 2021-12-23
CA3174380A1 (en) * 2020-07-27 2022-02-03 Stemcell Technologies Canada Inc. Systems and methods for differentiating hematopoietic cells
CN111808812B (zh) * 2020-08-31 2020-12-15 首都医科大学附属北京友谊医院 一种用于多能干细胞向造血干细胞分化的材料和方法
US12435308B2 (en) 2020-11-06 2025-10-07 Amniotics Ab Immunomodulation by amniotic fluid mesenchymal stem cells
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
CN112608895B (zh) * 2020-12-18 2024-02-27 深圳市济因生物科技有限公司 一种人多能干细胞分化的自然杀伤细胞及其制备方法与应用
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
CN117441010A (zh) 2021-04-07 2024-01-23 世纪治疗股份有限公司 从诱导多能干细胞产生α-βT细胞的组合物和方法
CA3210702A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Gene transfer vectors and methods of engineering cells
WO2022216524A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
JP2024519515A (ja) 2021-04-07 2024-05-15 センチュリー セラピューティクス，インコーポレイテッド 人工多能性幹細胞からガンマ－デルタｔ細胞を生成するための組成物および方法
AU2022269643A1 (en) 2021-05-05 2023-11-02 FUJIFILM Cellular Dynamics, Inc. Methods and compositions for ipsc-derived microglia
CA3231278A1 (en) 2021-09-10 2023-03-16 Deepika Rajesh Compositions of induced pluripotent stem cell-derived cells and methods of use thereof
WO2023039552A1 (en) * 2021-09-13 2023-03-16 Amprion, Inc. Inert matrices for qualitative and semi-quantitative seed amplification assays
WO2023110045A1 (en) 2021-12-15 2023-06-22 Y-Mabs Therapeutics, Inc. Scfv and antibodies with reduced multimerisation
EP4456912A1 (en) 2021-12-29 2024-11-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
US20250161359A1 (en) 2022-02-22 2025-05-22 Juno Therapeutics, Inc. Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
CN119365492A (zh) 2022-05-04 2025-01-24 世纪治疗股份有限公司 用hla-e和hla-g转基因工程化的细胞
CN119630695A (zh) 2022-06-08 2025-03-14 世纪治疗股份有限公司 表达cd16变体和nkg2d的遗传工程化细胞及其用途
US20250090582A1 (en) 2022-06-08 2025-03-20 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
WO2023240169A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
WO2024103017A2 (en) 2022-11-10 2024-05-16 Century Therapeutics, Inc. Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof
WO2024137677A1 (en) 2022-12-19 2024-06-27 FUJIFILM Holdings America Corporation Extracellular vesicle-enriched secretome composition derived from induced pluripotent stem cell derived-microglia and methods of use thereof
IL322654A (en) * 2023-02-16 2025-10-01 Syntax Bio Inc Systems for reprogramming cells towards the hematopoietic lineage and methods thereof
CN116426472A (zh) * 2023-06-08 2023-07-14 呈诺再生医学科技(北京)有限公司 一种促进造血干细胞或造血祖细胞分化为红细胞的诱导分化体系及其应用
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
WO2025207798A1 (en) 2024-03-26 2025-10-02 Century Therapeutics, Inc. Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof
WO2025207795A1 (en) 2024-03-26 2025-10-02 Juno Therapeutics, Inc. Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187371B1 (en) 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
WO1998003067A1 (en) 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
EP0986635A4 (en) 1997-01-10 2001-11-07 Life Technologies Inc SERUM SUBSTITUTE FOR EMBRYONIC STEM CELLS
DE60036540T2 (de) 1999-03-25 2008-07-03 Mitsubishi Tanabe Pharma Corp. Rho-kinase-inhibitoren für die vorbeugung oder behandlung von interstitieller pneumonie und pulmonaler fibrose
WO2000078351A1 (en) 1999-06-18 2000-12-28 Mitsubishi Pharma Corporation Osteogenesis promoters
CA2438501C (en) * 2001-02-14 2014-09-16 Leo T. Furcht Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
EP1463803B1 (en) * 2001-12-07 2018-02-14 Asterias Biotherapeutics, Inc. Hematopoietic cells from human embryonic stem cells
AU2002350352A1 (en) * 2001-12-21 2003-07-15 Mount Sinai Hospital Cellular compositions and methods of making and using them
US6943172B2 (en) 2002-01-23 2005-09-13 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
US6664266B2 (en) * 2002-03-14 2003-12-16 Children's Medical Center Corporation Axon regeneration with PKC inhibitiors
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
CA2785889A1 (en) * 2002-04-22 2003-10-30 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase c
US7723106B2 (en) * 2004-07-29 2010-05-25 Food Industry Research & Development Institute Stroma-free, serum-free, and chemically defined medium and method for ex vivo mononuclear cell expansion using the same
CA2557650A1 (en) 2004-03-08 2005-09-22 Wyeth Ion channel modulators
US7452718B2 (en) * 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
ES2383813T3 (es) * 2004-09-08 2012-06-26 Wisconsin Alumni Research Foundation Método de cultivo y cultivo de células madre embrionarias
WO2006050330A2 (en) 2004-11-01 2006-05-11 Wisconsin Alumni Research Foundation Platelets from stem cells
US20070077654A1 (en) 2004-11-01 2007-04-05 Thomson James A Platelets from stem cells
WO2006090882A1 (ja) 2005-02-23 2006-08-31 Foundation For Biomedical Research And Innovation 血管内皮前駆細胞の生体外増幅方法
US20070128669A1 (en) * 2005-11-28 2007-06-07 Institute For Chemical Genomics Serum-free expansion of cells in culture
JP2008099662A (ja) * 2006-09-22 2008-05-01 Institute Of Physical & Chemical Research 幹細胞の培養方法
EP2088190A4 (en) * 2006-11-09 2011-01-05 Japan Government METHOD FOR THE CULTURE AND PASSING OF AN EMBRYONAL PRIMATIVE STEM CELL AND METHOD FOR INDUCING THE DIFFERENTIATION OF THE EMBRYONAL STEM CELL
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
CA3123228A1 (en) 2008-03-27 2009-10-01 Asterias Biotherapeutics, Inc. Differentiation of primate pluripotent stem cells to hematopoietic lineage cells
WO2009135206A1 (en) * 2008-05-02 2009-11-05 Stem Cell Products, Inc. Method for production of mast cells from stem cells
US20110263016A1 (en) * 2008-09-25 2011-10-27 Rancourt Derrick E Expansion of Embryonic Stem Cells

Also Published As

Publication number Publication date
US20100279403A1 (en) 2010-11-04
CA2753679A1 (en) 2010-09-02
IL214818A0 (en) 2011-11-30
EP2401364A1 (en) 2012-01-04
KR20110122858A (ko) 2011-11-11
JP2015192681A (ja) 2015-11-05
KR101720961B1 (ko) 2017-03-29
US8372642B2 (en) 2013-02-12
AU2010217739B2 (en) 2015-09-03
CA2753679C (en) 2021-03-02
US10100282B2 (en) 2018-10-16
EP2401364B1 (en) 2015-04-22
AU2010217739A1 (en) 2011-09-08
US20130210141A1 (en) 2013-08-15
CN102388130B (zh) 2014-08-27
CN102388130A (zh) 2012-03-21
WO2010099539A1 (en) 2010-09-02
JP2012519005A (ja) 2012-08-23
IL214818A (en) 2014-07-31

Similar Documents

Publication Publication Date Title
JP5816100B2 (ja) 多能性細胞の分化
JP2012519005A5 (enExample)
AU2020264375B2 (en) Method for developing natural killer cells from stem cells
JP6189581B2 (ja) 幹細胞の分化のための方法および組成物
US20200157503A1 (en) Hemangio colony forming cells and non-engrafting hemangio cells
CN117264888A (zh) 一种制备造血干细胞和祖细胞的方法
HK40017506A (en) Method for developing natural killer cells from stem cells

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140911

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150925

R150 Certificate of patent or registration of utility model

Ref document number: 5816100

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D03

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250